Immunocore (NASDAQ:IMCR) Hits New 1-Year Low – Should You Sell?

Shares of Immunocore Holdings plc (NASDAQ:IMCR) hit a new 52-week low during trading on Friday . The stock traded as low as $28.84 and last traded at $29.03, with a volume of 34148 shares changing hands. The stock had previously closed at $30.31.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Thursday, October 24th. Morgan Stanley restated an “equal weight” rating and set a $35.00 price target (down previously from $74.00) on shares of Immunocore in a research report on Friday. UBS Group initiated coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 price target for the company. Needham & Company LLC reduced their price target on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $72.00 to $38.00 in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Trading Down 1.6 %

The stock has a 50 day moving average of $32.32 and a 200 day moving average of $35.48. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The firm has a market cap of $1.49 billion, a P/E ratio of -31.90 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. The company had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.59) EPS. As a group, equities research analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current year.

Institutional Trading of Immunocore

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Pier Capital LLC lifted its position in Immunocore by 1.4% in the third quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock valued at $2,568,000 after purchasing an additional 1,174 shares during the last quarter. XTX Topco Ltd lifted its position in Immunocore by 72.9% in the third quarter. XTX Topco Ltd now owns 15,459 shares of the company’s stock valued at $481,000 after purchasing an additional 6,516 shares during the last quarter. Wellington Management Group LLP lifted its position in Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock valued at $219,430,000 after purchasing an additional 668,382 shares during the last quarter. Two Sigma Advisers LP lifted its position in Immunocore by 65.6% in the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock valued at $23,587,000 after purchasing an additional 300,200 shares during the last quarter. Finally, State Street Corp lifted its position in Immunocore by 63.9% in the third quarter. State Street Corp now owns 76,671 shares of the company’s stock valued at $2,387,000 after purchasing an additional 29,897 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.